42 research outputs found
Copper Sorption by Coal Substances from Aqueous Solutions
The copper cations sorption by brown coal, humic acids and residual coal samples after the extraction of humic acid was studied by using the methods of spectroscopy FT-IR, EPR, Solid State CP/MAS 13C-NMR. Samples of lignite (brown coal) of the Tisulsky deposit (TL) of Kansk-Achinsk brown coal basin (Russia), its naturaloxidized form (NOLF), as well as samples of the humic acids (HA) extracted from them, and the residual coal after the extraction of humic acids (RC) were used as sorbents. The copper cations sorption process by the investigated samples depends on contribution of several mechanisms in varying degrees. It may be an ion exchange; complexation with the functional groups of the electron donor; complexation to form the bond Mez+ β HA due to the presence of the free Ο-electrons on the surface. The quantity of adsorbed copper cations depends on the functional and structural composition of the investigated samples. The copper cations sorption by the coals, humic acids and residual coals reduces the number of paramagnetic centers in the samples and the intensity of the NMR spectra. The copper cations sorption by HA from TL is determined by the significant contribution of the ion exchange process. HA from NOLF; initial TL and NOLF; RC TL and RC NOLF sorb copper cations mainly due to the formation of complexes with individual functional groups and the negatively charged surface portions. The data of 13C-NMR and EPR studies have shown that the aromatic structures make the main contribution to the complexation
ΠΠΎΡΡΠ½ΠΎ-ΠΌΡΡΠ΅ΡΠ½ΡΠ΅ ΠΏΠΎΡΠ΅ΡΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π°Π½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠΈΠΌ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡΠΎΠΌ
Ankylosing spondylitis (AS) is one of the most common autoinflammatory diseases that lead to early disability and high premature mortality rates. Along with lower bone mineral density, patients with AS are characterized by muscle mass decrease, such as sarcopenia. Musculoskeletal losses due to chronic immune inflammation and limited physical functioning significantly worsen prognosis and result in an increased risk of falls and fractures in patients with AS.The review considers the pathogenetic mechanisms of the relationship between AS and sarcopenia and the main approaches to treating degenerative changes in muscle tissue in patients with AS.ΠΠ½ΠΊΠΈΠ»ΠΎΠ·ΠΈΡΡΡΡΠΈΠΉ ΡΠΏΠΎΠ½Π΄ΠΈΠ»ΠΈΡ (ΠΠ‘) β ΠΎΠ΄Π½ΠΎ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΡΡ
Π°ΡΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠΈΡ
ΠΊ ΡΠ°Π½Π½Π΅ΠΉ ΡΡΡΠ°ΡΠ΅ ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈ Π²ΡΡΠΎΠΊΠΎΠΌΡ ΡΡΠΎΠ²Π½Ρ ΠΏΡΠ΅ΠΆΠ΄Π΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ. ΠΠ°ΡΡΠ΄Ρ ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ‘ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎ ΠΈ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ ΠΌΡΡΠ΅ΡΠ½ΠΎΠΉ ΠΌΠ°ΡΡΡ β ΡΠ°ΡΠΊΠΎΠΏΠ΅Π½ΠΈΡ. ΠΠΎΡΡΠ½ΠΎ-ΠΌΡΡΠ΅ΡΠ½ΡΠ΅ ΠΏΠΎΡΠ΅ΡΠΈ, ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π½ΡΠ΅ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈΠΌΠΌΡΠ½Π½ΡΠΌ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΈ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΠ½ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΡ
ΡΠ΄ΡΠ°ΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ· ΠΈ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»ΠΈΠ²Π°ΡΡ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΠΈΡΠΊ ΠΏΠ°Π΄Π΅Π½ΠΈΠΉ ΠΈ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ‘.Π ΠΎΠ±Π·ΠΎΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΠ‘ ΠΈ ΡΠ°ΡΠΊΠΎΠΏΠ΅Π½ΠΈΠΈ ΠΈ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ Π΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΌΡΡΠ΅ΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΠ‘
ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ Π½Π° ΡΠΎΠ½Π΅ 4-Π»Π΅ΡΠ½Π΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΈΡΡΠΊΡΠΈΠΌΠ°Π±ΠΎΠΌ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅, ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΡΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ
Objective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic therapy option, all the patients were allocated into two groups: 1) 44 patients who received combination therapy with RTM and methotrexate (MT); 2) 35 patients who had MT monotherapy. BMD was estimated by dual-energy X-ray absorptiometry using an Excell XR-46 stationary dualenergy X-ray bone densitometer (Norland, USA).Results. There was a statistically significant increase in femoral neck BMD and T score as compared to the baseline values in the RTM group after 3 years of follow-up. The MT monotherapy group showed no statistically significant densitometric changes in the femoral neck. The similar positive BMD changes were observed 4 years following RTM and MT therapy.Conclusion. Following 2 therapy cycles, femoral neck BMD parameters were noted to be stabilized in the patients with RA. After 3 therapy cycles, there was a positive densitometric change that remained by the fourth therapy cycle.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ (ΠΠΠ) ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° Π½Π° ΡΠΎΠ½Π΅ 4-Π»Π΅ΡΠ½Π΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΈΡΡΠΊΡΠΈΠΌΠ°Π±ΠΎΠΌ (Π Π’Π) Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅, ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΡΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ (Π Π).ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π½Π°Ρ
ΠΎΠ΄ΠΈΠ»ΠΎΡΡ 79 ΠΆΠ΅Π½ΡΠΈΠ½ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅ Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Π Π. ΠΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Π±ΡΠ»ΠΈ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ Π² Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ: 1-Ρ Π³ΡΡΠΏΠΏΠ° (n=44) ΠΏΠΎΠ»ΡΡΠ°Π»Π° ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π Π’Π ΠΈ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠΎΠΌ (ΠΠ’); 2-Ρ Π³ΡΡΠΏΠΏΠ° (n=35) β ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΠ’. ΠΠΠ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄Π²ΡΡ
ΡΠ½Π΅ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΉ Π°Π±ΡΠΎΡΠ±ΡΠΈΠΎΠΌΠ΅ΡΡΠΈΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ Π΄Π²ΡΡ
ΡΠ½Π΅ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠ° Exceell XR-46 (Norland, Π‘Π¨Π).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΠΠ ΠΈ Π’-ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΠ΅ΡΠ΅Π· 3 Π³ΠΎΠ΄Π° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π² Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
Π Π’Π. Π Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΠ’, ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ³ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ. ΠΠ½Π°Π»ΠΎΠ³ΠΈΡΠ½Π°Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΠΠ Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ ΡΠ΅ΡΠ΅Π· 4 Π³ΠΎΠ΄Π° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π Π’Π ΠΈ ΠΠ’.ΠΡΠ²ΠΎΠ΄Ρ. ΠΠΎΡΠ»Π΅ 2 ΠΊΡΡΡΠΎΠ² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΠΠ ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π Π. ΠΠΎΡΠ»Π΅ 3 ΠΊΡΡΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»Π°ΡΡ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΠΊΠΎΡΠΎΡΠ°Ρ ΡΠΎΡ
ΡΠ°Π½ΡΠ»Π°ΡΡ ΠΈ ΠΊ 4-ΠΌΡ ΠΊΡΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
Objective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic therapy option, all the patients were allocated into two groups: 1) 44 patients who received combination therapy with RTM and methotrexate (MT); 2) 35 patients who had MT monotherapy. BMD was estimated by dual-energy X-ray absorptiometry using an Excell XR-46 stationary dualenergy X-ray bone densitometer (Norland, USA).Results. There was a statistically significant increase in femoral neck BMD and T score as compared to the baseline values in the RTM group after 3 years of follow-up. The MT monotherapy group showed no statistically significant densitometric changes in the femoral neck. The similar positive BMD changes were observed 4 years following RTM and MT therapy.Conclusion. Following 2 therapy cycles, femoral neck BMD parameters were noted to be stabilized in the patients with RA. After 3 therapy cycles, there was a positive densitometric change that remained by the fourth therapy cycle